Loss-Making Initiator Pharma A/S (STO:INIT) Expected To Breakeven In The Medium-Term

Initiator Pharma A/S (STO:INIT) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. With the latest financial year loss of kr.13m and a trailing-twelve-month loss of kr.12m, the kr216m market-cap company alleviated its loss by moving closer towards its target of breakeven. Many investors are wondering about the rate at which Initiator Pharma will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

According to the 2 industry analysts covering Initiator Pharma, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2025, before generating positive profits of kr.22m in 2026. The company is therefore projected to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 88%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we won’t go into details of Initiator Pharma's upcoming projects, however, take into account that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

View our latest analysis for Initiator Pharma

One thing we’d like to point out is that The company has managed its capital judiciously, with debt making up 6.6% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Initiator Pharma, so if you are interested in understanding the company at a deeper level, take a look at Initiator Pharma's company page on Simply Wall St. We've also put together a list of key factors you should further research:

1. Historical Track Record: What has Initiator Pharma's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Initiator Pharma's board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.